Skip to main content
. 2022 Apr 29;8(17):eabl6339. doi: 10.1126/sciadv.abl6339

Fig. 1. Patients exhibit distinct responses to BRAFi + MEKi following prior KI treatment.

Fig. 1.

(A) Responses of tumor lesions to D/T or E/B were retrospectively analyzed across 81 pretreated or naïve patients. (B) Individual tumor responses were compared between pretreated and naïve cohorts (number of patients and Fisher’s exact test P value shown). (C) Responses of individual tumor lesions to D/T in BRAFi/MEKi-naïve patients or E/B in BRAFi/MEKi-pretreated patients were retrospectively analyzed by radiologic imaging. Lesion responses were binned according to organ site in patients with metastatic melanoma, reported as the number of organ sites showing lesion response and corresponding percentages in parentheses. (D) Odds ratios (means ± 95% CI) are shown corresponding to data in (C).